AlphaMed Press earns CEO Cancer Gold Standard accreditation

NewsGuard 100/100 Score

AlphaMed Press has received CEO Cancer Gold Standard accreditation, recognizing the organization's commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

“Medicine teaches us that a team approach is best to prevent and treat cancer”

William C. Weldon, chairman and chief executive officer of Johnson & Johnson, chairs the CEO Roundtable on Cancer, a nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard, in collaboration with the National Cancer Institute, many of its designated cancer centers, and leading health non-profit organizations and professionals. Today, nearly one million and a quarter employees and family members are benefiting from the vision and leadership of employers who have chosen to become Gold Standard accredited.

"The leadership and commitment to employee health of Gold Standard organizations is exemplary," said Weldon. "AlphaMed Press is a premier publisher of internationally recognized scientific journals such as STEM CELLS and THE ONCOLOGIST and we hope that they will serve as a model for other employers, large and small, for-profit and not-for-profit, to foster a workplace culture of health and wellness."

The CEO Cancer Gold Standard calls for companies to evaluate their health benefits and corporate culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use; encouraging physical activity; promoting healthy diet and nutrition; detecting cancer at its earliest stages; and providing access to quality care, including participation in clinical trials.

"Medicine teaches us that a team approach is best to prevent and treat cancer," said Ann Murphy, PhD, President of AlphaMed Press. "Receiving the CEO Cancer Gold Standard™ reflects AlphaMed Press's commitment to being an active member of this team and we encourage other companies to proactively invest in their employees' future well being by embracing the Gold Standard."

Other organizations joining AlphaMed Press in championing this workplace-based effort to eliminate cancer as a public health threat include: Aetna, Aldagen, Inc., the American Cancer Society's National Home Office and Mid-South Division, the American Legacy Foundation, the American Society of Clinical Oncology, Aptuit, AstraZeneca, C-Change, Cigna, Dana-Farber Cancer Institute, Duke Medicine, Edelman, Enzon Pharmaceuticals, Fox Chase Cancer Center, GlaxoSmithKline, Hawaii Pacific Health, Hogan & Hartson, Independence Blue Cross, Jenner & Block, Johnson & Johnson, the Lance Armstrong Foundation, LiDestri Foods, M. D. Anderson Cancer Center, MDU Resources, Meridian Health, Millennium: The Takeda Oncology Company, Minot State University, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute, Nevada Cancer Institute, Novartis, The Oncology Nursing Society, OSI Pharmaceuticals, Pfizer, PhRMA, PPD, Pride, Inc., Quest Diagnostics, Quintiles Transnational, sanofi-aventis, SAS Institute, St. Barnabas Health Care System, State Farm, Susan G. Komen for the Cure, The University of North Dakota, US Oncology, Valeant Pharmaceuticals, Vanderbilt-Ingram Cancer Center, Virtua Health, WCA Hospital, Wistar Institute and XCelience, LLC.

Source:

 AlphaMed Press

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels